Clinical Trial for Cystic Fibrosis Patients
NCT02443688 – Phase 2 Cystic Fibrosis – Completed
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of acebilustat Administered Orally Once-Daily for 48 Weeks in Adult Patients with Cystic Fibrosis.
Find out more about this trial – http://clinicaltrials.gov/show/NCT02443688.
Celtaxsys, with continued support from the CF Foundation, has commenced preparations for designing and executing the acebilustat Phase 3 clinical program.